Heron Therapeutics (HRTX) Projected to Post Earnings on Thursday

Heron Therapeutics (NASDAQ:HRTX) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $39.5330 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Heron Therapeutics Price Performance

Shares of Heron Therapeutics stock opened at $1.21 on Thursday. The business’s fifty day moving average price is $1.33 and its 200 day moving average price is $1.29. Heron Therapeutics has a twelve month low of $1.00 and a twelve month high of $2.68. The company has a current ratio of 2.56, a quick ratio of 1.78 and a debt-to-equity ratio of 19.89. The stock has a market capitalization of $221.87 million, a P/E ratio of -13.44 and a beta of 1.25.

Institutional Investors Weigh In On Heron Therapeutics

Large investors have recently added to or reduced their stakes in the company. Advisory Services Network LLC increased its stake in Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock worth $25,000 after buying an additional 18,114 shares during the period. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Heron Therapeutics during the second quarter valued at about $26,000. Voleon Capital Management LP purchased a new stake in shares of Heron Therapeutics during the third quarter worth about $34,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Heron Therapeutics during the third quarter worth about $34,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Heron Therapeutics in the second quarter worth about $43,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HRTX has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Heron Therapeutics in a research report on Friday, January 9th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.